Skip to NavigationSkip to content


Gilead's CAR-T therapy Yescarta rejected for NHS use in Scotland

It’s bad news for Scottish patients living with aggressive forms of non-Hodgkin lymphoma (NHL) as it emerges that the Scottish Medicines Consortium has chosen to reject Gilead’s CAR-T therapy Yescarta (axicabtagene ciloleucel).

The decision means that patients who may have exhausted all other avenues of treatment will not be able to receive the treatment on the NHS in Scotland, with many not expected to survive longer than six months in these cases.

Gilead shares drop 4% after failure of NASH drug to meet primary endpoint

Gilead’s treatment for the progressive fatty liver disease, NASH, has failed to meet its primary goal in a phase 3 trial, causing shares in the company to fall by as much as 4%.

Gilead’s treatment for Nonalcoholic Steatohepatitis (NASH), a drug called selonsertib, did not meet its primary endpoint in a randomised, double-blind, placebo controlled Phase 3 trial involving 877 patients.

Gilead inks $1.8 bn deal with immuno-oncology biotech Agenus

California-based firm Gilead Sciences and Massachusetts-based immuno-oncology biotech Agenus have announced that they have entered into a partnership focused on the development and commercialisation of up to five novel immuno-oncology therapies, in a deal worth up to $1.8 billion.

Under the terms of the agreement Agenus will receive $150 million upon closing which includes $120 million in cash along with an equity investment of $30 million. However Agenus will be eligible to receive up to $1.7 billion in potential future fees and milestones.

Gilead and Scholar Rock collaborate on fibrosis in deal worth more than $80m

Image Credit: Yale Rosen

California-based antiviral drugs specialist Gilead Sciences has entered into a strategic partnership with Cambridge, Massachusetts-based biotech Scholar Rock as part of an effort to discover and develop treatments for fibrotic diseases.

The collaboration will be focused towards the discovery and development of highly specific inhibitors of transforming growth factor beta (TGFβ) activation for the treatment of diseases related to fibrosis.

Pharma in 2018: Looking back, looking forward

Published on 18/12/18 at 12:31pm

2018 has been a year characterised by uncertainty, but also significant leaps in research, access, and industry deals. With 2019 bringing a host of new challenges, not least of which is Brexit, Pharmafocus spoke to industry figures to ask what the past year meant, and what their projections are going forward.

Hilary Hutton-Squire, General Manager, UK and Ireland, Gilead Sciences

What would you say have been the big developments of the year?

The December issue of Pharmafocus is available to read online now!

The December edition of Pharmafocus is live and available to read online now!

Brexit continues to dominate the headlines inside and outside the industry, but for our final issue of 2018, we have a slew of content and news to round out the year.

Gilead names Roche veteran Daniel O'Day as new CEO

Almost half a year since it was revealed that Gilead’s Dr John Milligan would be stepping down from his role as CEO alongside Chairman Dr John Martin, it has emerged that Daniel O’ Day, current CEO of Roche’s pharmaceutical business, will be stepping in to helm the company.

O’ Day has been with Roche since 1987, holding a number of roles in the US, before moving to the company’s headquarters in Switzerland in 1998 to take on leadership roles in Global Marketing and Lifecycle Manage

NICE give go-ahead to Gilead's Yescarta for adults with lymphoma

The NHS cost effectiveness body NICE has approved Gilead’s Yescarta for treatment of come adults with lymphoma.

Gilead’s treatment will be funded through the Cancer Drugs Fund for adults with relapsed or refractory diffuse large B-cell lymphoma or primary mediastinal large B-cell lymphoma, two aggressive subtypes of non-Hodgkin lymphoma.

Gilead's CAR-T therapy Yescarta shows two-year response duration in large B-cell lymphoma

Gilead has gone head to head with Novartis at the American Society of Hematology (ASH) Annual Meeting 2018, meeting the latter’s reveal of data on rival Kymriah with study findings of its own CAR-T therapy Yescarta (Axicabtagene Ciloleucel).

The findings revealed that after a minimum follow-up of two years after a single Yescarta infusion – and a median follow-up of 27.1 months – 39% of participants achieved an ongoing response in the treatment of refractory large B-cell lymphoma; in this group, 93% of those experiencing response at 12 months went on to maintain a response after 24

NHS England appoves Gilead's CAR T therapy Yescarta

Gilead’s CAR T therapy Yescarta is set to be made available on the NHS in England for adults with aggressive non-Hodgkin lymphoma, it was announced today.

Although NICE rejected the £300,000 per patient treatment in August of this year, NHS England has come to a confidential agreement with Yescarta manufacturer Gilead Sciences.

Thus an estimated 200 patients a year could benefit from the personalised treatment according to NHS England.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches